Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Johnson & Johnson (J&J)

Status and phase: Terminated; Phase 3

Conditions: Anemia; Cancer

Treatments: Drug: Epoetin alfa

Study type: Interventional

Funder types: Industry

Identifiers

NCT00083434

CR010549

EPO-CAN-303

Details and patient eligibility

About

The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older
• Body weight >/= 99lbs
• ECOG 0-2
• Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
• Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women

Exclusion criteria

• History of or concurrent second malignancy
• Evidence of primary or metastatic malignancy involving the Central Nervous System